Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/209126
Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
With the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA)vaccinations, we have been witnessing a new era in vaccinology because these vaccines do not contain viral proteins but mRNA or viral vectors that instruct the cells to make viralspecific protective antibodies. To effectively fight SARS-CoV-2 infection, however, these vaccines need to induce both humoral and cell-mediated immune responses, with antibodies that block viral replication and viral-specific T cells that kill viral-infected cells and generate antibodyproducing plasma cells and long-lived memory cells.
Citació
Citació
DALAKAS, Marinos C. and DALMAU OBRADOR, Josep. Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology. Neurology-Neuroimmunology & Neuroinflammation. 2022. Vol. 9, num. 4. ISSN 2332-7812. [consulted: 9 of September of 2026]. Available at: https://hdl.handle.net/2445/209126